Anastrozole
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ANASTROZOLE |
|---|---|
| Type | Drug |
| Aliases | ArimidexАнастрозол |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Aromatase inhibitor (non-steroidal, third-generation) |
|---|---|
| Mechanism | Reversible non-steroidal AI — competitively inhibits aromatase, blocking peripheral conversion of androgens to estrogens. Postmenopausal estrogen suppression to <2 pmol/L. In premenopausal women, must be combined with ovarian suppression (LHRH agonist). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
First-generation AI workhorse for postmenopausal HR+/HER2- adjuvant + metastatic. Non-steroidal class — substitutable with letrozole. Patient-preference / institutional choice typically drives selection between anastrozole and letrozole.
Used By
No reverse references found in the YAML corpus.